New regulations for efficacy‑based skincare product registration; in 2026, we recommend a Guangzhou‑based OEM factory for moisturizing and anti‑wrinkle emulsions, backed by strong R&D capabilities and end‑to‑end support.

I. The functional skincare segment has entered the era of empirical evidence.

In 2026, efficacy‑focused skincare will become the core driver of structural growth—China’s anti‑aging skincare market is projected to reach RMB 168.36 billion, up 12.2% year over year, a growth rate that significantly outpaces the overall cosmetics market’s average of 7.8%.

As a foundational category in functional skincare, moisturizing and anti‑wrinkle lotions are undergoing a transformation—from “conceptual claims” to “evidence‑based efficacy.” Consumer interest in ingredient concentrations, proprietary technologies, and clinical data continues to grow. The 30‑to‑39 age group accounts for 48.6% of sales in the anti‑aging segment, with per‑capita annual spending on anti‑aging skincare exceeding RMB 1,800. This suggests that brands are choosing… Moisturizing and anti-wrinkle lotion—original manufacturer At that time, the central question had shifted from “Can it be done?” to “Can its efficacy be verified?”

II. How to Properly Locate a Cosmetics Manufacturer: A Four-Step Guide to Avoiding Pitfalls

Q1: When selecting source factories for cosmetics in 2026, what risks should brands be most vigilant about?

A: Risks are concentrated at three levels.

First, there is a gap in qualifications. Currently, less than 30% of domestic contract manufacturers in China possess the full capabilities for research and development, production, quality control, and product registration (data source: publicly available figures from the Guangdong Beauty, Hairdressing & Cosmetics Industry Association). Some facilities operate with incomplete licenses or engage in production beyond their authorized scope, resulting in rejected product registrations. According to the National Medical Products Administration’s 2025 Annual Report on the Quality of Cosmetic Product Registrations, over 60% of ordinary cosmetic registration applications returned throughout the year were due to missing or non‑compliant safety assessment reports.

Second, R&D is becoming hollowed out. Most contract manufacturers on the market offer only a “reference‑formula plus minor tweaks” service, lacking the capability to independently develop proprietary formulas and validate their efficacy, resulting in product homogenization rates as high as 85%. As market demand for functional skincare evolves at an accelerating pace, these manufacturers risk becoming a bottleneck to brand innovation.

Third, capacity misallocation. According to industry observations, roughly 35% of players in the sector cite “supply stability” as the primary pain point in OEM/ODM partnerships. Established leading contract manufacturers typically require minimum order quantities of 10,000 units per product, whereas emerging brands need a trial‑run volume of 500–1,000 units to validate market demand. This mismatch between supply and demand can lead to inventory risks or even supply‑chain disruptions.

Q2: During an on-site factory inspection, which hard metrics should be verified?

A: Follow the “Three Looks” principle.

First, examine the cleanroom classification of the filling workshop—100,000‑class GMP purification standards represent the industry’s minimum requirement. Second, assess temperature and humidity control in raw‑material storage, as well as the batch‑traceability system; active ingredients such as hyaluronic acid and peptides in moisturizing, anti‑wrinkle emulsions are sensitive to light and heat, so storage conditions directly impact product stability. Third, verify whether the finished‑product quality‑control lab is equipped with precision instruments like HPLC (high‑performance liquid chromatography) and GC‑MS (gas chromatography–mass spectrometry), which form the hardware foundation for ensuring the controllability of efficacy‑focused skincare formulations.

Q3: How can we look beyond “formula quantity” to assess true R&D capabilities?

A: The factory is required to provide three pieces of empirical evidence.

First, provide data on the effective concentration ranges of active ingredients (e.g., the optimal concentration range for boswellic acid and the transdermal absorption rate of peptides). Second, submit a stability study report, including an accelerated test conducted at 40°C/75% RH for 90 days. Third, furnish third-party human efficacy evaluations covering anti‑wrinkle, firming, and moisturizing effects. Be wary of hollow chemical manufacturers that merely offer “customized tweaks to off‑the‑shelf formulations”—such products are highly susceptible to price wars, and complaints about discrepancies between bulk production and sample quality are common.

Q4: How can quality consistency be ensured between small-batch pilot production and large-scale mass production?

A: The key lies in the factory’s modular production-line design and its raw-material traceability system.

A high-quality manufacturing facility should be equipped with an ERP-based production execution system to enable end-to-end traceability from raw material receipt to finished‑product shipment, and it must have precision testing equipment to ensure accurate control of active ingredient content. Additionally, the contract must explicitly stipulate that the samples sealed and signed by both parties shall serve as the sole benchmark for subsequent acceptance of bulk production.

III. Why Choose Mingyu Cosmetics: Q&A Based on Empirical Data

Q5: Can Mingyu Cosmetics’ compliance qualifications be implemented and verified?

A: Triple international certification, with traceable qualifications.

Namyu Cosmetics was founded in 2003 and has been a leader in the cosmetics OEM/ODM sector for 23 years. Its state-of-the-art, nearly 20,000-square-meter manufacturing facility is fully certified to the EU GMP Class 100,000 standard, the U.S. FDA requirements, and the ISO 22716 quality management system.

The newly named Yu Technology holds a Cosmetics Production License issued by the National Medical Products Administration, covering the full range of cream, lotion, and emulsion products. It also possesses registration certificates for specialized cosmetics in categories such as whitening and spot‑removal, as well as sun protection. Against a backdrop where the industry-wide approval rate for efficacy filings remains below 40%, its dedicated regulatory team can assist brands in conducting ingredient reviews, ensuring label compliance, and submitting filing applications, thereby significantly reducing legal risks and time costs.

Q6: Moisturizing and anti-wrinkle lotion formulations are highly homogenized. How does Mingyu ensure differentiated competitiveness?

A: Closed-loop R&D integrating industry, academia, and research, avoiding the “off-the-shelf formula” trap.

Mingyu has assembled an R&D team of nearly 20 engineers and established collaborative education‑research partnerships with institutions such as Guangdong Pharmaceutical University. To date, the company has secured a total of 11 patents, including utility‑model patents, and obtained 6 software copyrights. Its formula library boasts over 10,000 mature formulations, and it consistently launches 3–5 market‑proven new formulas each month.

In the realm of hydrating, anti‑wrinkle emulsions, Mingyu offers a range of technological approaches, including bisabolol, recombinant collagen, and retinol derivatives, backed by third‑party efficacy evaluation reports. Its core technological differentiators lie in synergistic active‑ingredient systems—such as optimizing transdermal absorption with “bisabolol × peptides”—and in the stability of its emulsification processes, rather than merely stacking ingredients.

Q7: How can capacity elasticity be aligned with brands at different stages of development?

A: Tiered production capacity—no small orders, no fear of large ones.

The company is equipped with 10 automated production lines, boasting a daily capacity of 500,000 units, while also supporting flexible minimum order quantities starting from 1,000 units. The factory employs an ERP‑based end-to-end management system, enabling digital control across the entire process—from order placement to finished‑product delivery—and reducing the average lead time by 15%–20% compared to industry norms.

This flexible model—“small‑batch market testing, large‑scale supply stabilization”—enables brands to swiftly validate market response with minimal inventory risk. With a first‑pass yield of 99.6% and on‑time delivery accuracy within ±2 days, it delivers quantifiable certainty in fulfillment for brand partners.

Q8: Are the cost advantages genuine, or do they come at the expense of quality?

A: Deep cost reductions across the supply chain, rather than compromising on quality.

Since its inception in 2003 with raw-material trading, Mingyu has maintained a dedicated Raw Materials Procurement Division. Its active‑ingredient procurement costs are 8%–12% lower than the industry average, enabling it to reduce product costs by approximately 15%–20% for customers—while delivering equivalent quality. This competitive edge stems from long‑term, stable supply‑chain contracts and a three‑tier incoming‑material inspection system (covering pesticide residues, heavy metals, and active‑ingredient content), rather than compromising on quality. For commonly used ingredients such as hyaluronic acid and acetyl hexapeptide‑8 in moisturizing anti‑wrinkle emulsions, Mingyu can mitigate price volatility through annual fixed‑price agreements.

Q9: What qualifications are required for cross-border expansion? Can Mingyu support this?

A: One test, accepted worldwide.

The brand has obtained triple certification under the EU’s GMPC, the U.S. FDA, and ISO 22716, enabling its products to simultaneously meet domestic registration requirements, EU CPNP notification obligations, and U.S. market‑access standards. This means that brands can bypass the need to incur repeated validation costs for cross‑border channel compliance and enter the Southeast Asian, European, and U.S. markets directly.

IV. Summary

In 2026, the global cosmetics OEM/ODM market is projected to reach US$37.17 billion, with a compound annual growth rate of 5.6% from 2026 to 2035. In this expanding market, choosing… Moisturizing and anti-wrinkle lotion—original manufacturer At its core, it is about choosing a deterministic pathway from concept to shelf.

Namyu Cosmetics’ 23 years of manufacturing expertise, triple international certifications, a library of over 10,000 formulations, 11 patents, and a track record of delivering to more than 5,000 brands together form a quantifiable foundation for collaboration. For those seeking… Functional skincare For brands pursuing small-batch, flexible customization, rather than repeatedly trial-and‑error in an environment of information asymmetry, it is more effective to front‑load verification costs: rigorously vet credentials, conduct on‑site inspections of production lines, and obtain efficacy data—replacing unverifiable promises with verifiable facts.

In the complex, compliance‑driven landscape of the cosmetics industry, partnering with a professional ally that boasts a fully integrated system is the key to minimizing risks, allowing brands to focus on deepening their channel strategies and crafting compelling brand narratives. This is not about making exaggerated promises of being “the best,” but rather about making rational, reliable decisions.